Form 4: Nkarta Director Ali Behbahani Granted 46,000 Stock Options

Nkarta, Inc. Director Ali Behbahani was granted 46,000 stock options with an exercise price of $1.83, vesting fully by June 5, 2026, or earlier under specific conditions.

Summary

• Ali Behbahani, a Director of Nkarta, Inc. (NKTX), was granted 46,000 stock options.
• The transaction date for this grant was June 5, 2025.
• Each stock option has an exercise price of $1.83.
• The options are set to expire on June 4, 2035.
• The shares subject to the option will vest 100% on the earlier of June 5, 2026, or the day immediately preceding the first annual meeting of Nkarta's stockholders after the grant date.
• Full vesting will also occur upon a 'change in control' of Nkarta or the Reporting Person's separation from service due to death or disability.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a standard compensation practice that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, as the options gain value if the company's stock price increases.
• The options have a long expiration date (June 4, 2035), providing a significant window for potential value realization.

Risks

• The value of the stock options is dependent on the future performance of Nkarta's stock price; if the stock price does not exceed the exercise price of $1.83, the options may expire worthless.
• The vesting conditions mean the director must remain with the company for a specified period (or until a change in control/death/disability) to fully realize the benefit of the options.

Future Outlook

The grant of stock options with specific vesting conditions indicates a future alignment of the director's incentives with the long-term performance and strategic goals of Nkarta, Inc., aiming for value creation over the vesting period and beyond.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, serving as a key component of executive and director compensation packages to attract, retain, and incentivize leadership by aligning their financial interests with shareholder value creation.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across industries, including biotechnology, aligning director incentives with long-term company performance.
• The vesting schedule, which includes time-based vesting and accelerated vesting upon change of control or specific personal events, is typical for such equity awards in publicly traded companies.

Corporate Governance

Related Party Transactions

• The grant of stock options to Ali Behbahani, a Director of Nkarta, Inc., constitutes a related party transaction as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised, but it primarily serves to align the director's interests with shareholder value creation.
• Director (Ali Behbahani): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest according to the specified schedule, with the earliest full vesting on June 5, 2026, or the day before the first annual stockholders' meeting after the grant date.
• The director may choose to exercise the options at any time after vesting and before the expiration date of June 4, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Nkarta, NKTX, stock options, insider transaction, Form 4, director compensation, equity grant, vesting